Cargando…
Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches
BACKGROUND: Cytotoxic CD8(+) T cell-based cancer immunotherapy has been extensively studied and applied, however, tumor cells are known to evade immune responses through the expression of immune checkpoints, such as programmed death ligand 1 (PD-L1). To overcome these issues, antibody-based immune c...
Autores principales: | Won, Ji Eun, Byeon, Youngseon, Wi, Tae In, Lee, Chan Mi, Lee, Ju Hyeong, Kang, Tae Heung, Lee, Jeong-Won, Lee, YoungJoo, Park, Yeong-Min, Han, Hee Dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886443/ https://www.ncbi.nlm.nih.gov/pubmed/35228265 http://dx.doi.org/10.1136/jitc-2021-003928 |
Ejemplares similares
-
Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy
por: Lauret Marie Joseph, Elodie, et al.
Publicado: (2021) -
Dual receptor T cells mediate effective antitumor immune responses via increased recognition of tumor antigens
por: Jang, Hyun J, et al.
Publicado: (2023) -
IL-31 induces antitumor immunity in breast carcinoma
por: Kan, Tal, et al.
Publicado: (2020) -
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
por: Simonds, Erin F, et al.
Publicado: (2021) -
Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion
por: Ren, Yijie, et al.
Publicado: (2022)